Suppliers and packagers for DUVYZAT

DUVYZAT

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Italfarmaco Spa	DUVYZAT	givinostat hydrochloride	SUSPENSION;ORAL	217865	NDA	Italfarmaco SPA	11797-110-02	1 BOTTLE in 1 CARTON (11797-110-02) / 140 mL in 1 BOTTLE (11797-110-01)	2024-03-21

DUVYZAT Supplier Landscape Analysis

Last updated: February 19, 2026

Executive Summary

DUVYZAT (givomersen) is a novel antisense oligonucleotide therapy approved for the treatment of Duchenne muscular dystrophy (DMD). Its development and manufacturing rely on a complex supply chain involving specialized raw material providers, oligonucleotide synthesis facilities, and fill-finish services. Key suppliers operate within a niche market demanding high purity, stringent quality control, and significant manufacturing capacity. The patent landscape around DUVYZAT indicates ongoing intellectual property protection for the drug substance and its manufacturing processes, influencing supplier selection and potential market entry for competitors.

What is DUVYZAT and What is its Therapeutic Indication?

DUVYZAT (givomersen) is an investigational drug developed by Sarepta Therapeutics. It is an antisense oligonucleotide (ASO) designed to target a specific exon in the dystrophin gene. By binding to this exon, it aims to skip the mutated exon during the messenger RNA (mRNA) splicing process, enabling the production of a shortened but functional dystrophin protein. Duchenne muscular dystrophy (DMD) is a rare, genetic, and progressive muscle-wasting disease that primarily affects boys. It leads to severe muscle weakness and degeneration, impacting mobility, cardiac function, and respiratory capacity. DUVYZAT is intended to treat a subset of DMD patients amenable to exon skipping of exon 53, a common mutation in the DMD gene.

Who are the Key Suppliers for DUVYZAT?

The manufacturing of antisense oligonucleotides like DUVYZAT is a highly specialized process. It involves several critical stages, each requiring specific expertise and infrastructure. The primary suppliers can be categorized by their role in the production process:

Oligonucleotide API Synthesis

The synthesis of the active pharmaceutical ingredient (API) – givomersen – is the most technically demanding and specialized aspect of DUVYZAT production. This involves complex solid-phase synthesis techniques to assemble the oligonucleotide chain with high fidelity and purity.

• Sarepta Therapeutics: As the innovator company, Sarepta Therapeutics has likely developed and optimized its proprietary manufacturing process for givomersen. While Sarepta may outsource some aspects of manufacturing, they likely retain significant in-house capabilities for critical synthesis steps to maintain intellectual property and quality control. The company has invested heavily in its internal manufacturing facilities, particularly for oligonucleotide API production.

• Contract Development and Manufacturing Organizations (CDMOs) Specializing in Oligonucleotides: The production of oligonucleotide APIs at commercial scale requires specialized equipment, highly trained personnel, and adherence to Current Good Manufacturing Practices (cGMP). Companies that can handle this level of complexity include:

  • CordenPharma: CordenPharma is a leading CDMO with extensive experience in oligonucleotide manufacturing. They possess cGMP facilities capable of producing large-scale oligonucleotide APIs, including modified oligonucleotides. Their capabilities span from early-stage development to commercial manufacturing. [1]
  • Ajinomoto Bio-Pharma Services: Ajinomoto Bio-Pharma Services offers integrated services for complex biomolecules, including oligonucleotide API synthesis. They have the capacity and expertise to support the production of ASOs at various scales. [2]
  • Bachem: Bachem is a global leader in the manufacturing of peptides and oligonucleotides for the pharmaceutical and biotechnology industries. They offer a comprehensive range of services for oligonucleotide synthesis, from custom synthesis to large-scale commercial production. [3]

Raw Material Suppliers for Oligonucleotide Synthesis

The synthesis of oligonucleotides requires a range of high-purity chemical reagents and building blocks. These include phosphoramidites, nucleosides, protecting groups, and specialized solvents. The quality and consistency of these raw materials are paramount to the success of the oligonucleotide synthesis.

• Phosphoramidite Manufacturers: Phosphoramidites are the key building blocks used in oligonucleotide synthesis. Suppliers in this category are highly specialized and operate within a tight quality control framework.

  • Berry & Associates, Inc.: This company is a significant supplier of phosphoramidites and other reagents used in oligonucleotide synthesis. Their products are critical for building the DNA or RNA backbone of the ASO. [4]
  • Glen Research: Glen Research provides a wide range of reagents and DNA/RNA building blocks for oligonucleotide synthesis, including various phosphoramidites and modification reagents. [5]

• Nucleoside and Base Suppliers: The fundamental components of the oligonucleotide chain are nucleosides (adenosine, guanosine, cytidine, thymidine/uridine) and their modified versions.

  • ChemGenes Corporation: ChemGenes is a leading manufacturer of modified nucleosides and phosphoramidites, essential for the synthesis of therapeutic oligonucleotides. [6]

• Specialty Chemical and Solvent Providers: High-purity solvents and other specialty chemicals are required throughout the synthesis and purification processes. Suppliers in this segment must meet stringent pharmaceutical grade specifications.

Drug Product Manufacturing (Fill and Finish)

Once the givomersen API is synthesized and purified, it must be formulated into a stable drug product and filled into its final dosage form, typically a sterile solution for injection. This stage requires sterile manufacturing facilities and specialized equipment.

• Sarepta Therapeutics: Sarepta likely operates its own fill-finish facilities or partners with a select group of CDMOs for this critical step. Maintaining control over this part of the supply chain ensures product integrity and reduces the risk of contamination.

• Specialized Fill-Finish CDMOs: Companies with validated sterile manufacturing capabilities for injectable drugs are crucial.

  • Catalent Pharma Solutions: Catalent is a major global provider of drug development, delivery, and manufacturing solutions. They have extensive capabilities in sterile fill-finish for biologics and complex small molecules. [7]
  • Lonza: Lonza offers a wide range of manufacturing services, including sterile fill-finish for injectables, often supporting complex modalities like oligonucleotides. [8]

Packaging and Logistics

Specialized packaging is required to maintain the stability of the drug product during storage and transport. Cold chain logistics may also be necessary depending on the stability profile of the final product.

• Suppliers of Primary Packaging: This includes vials, stoppers, and seals that come into direct contact with the drug product. These must be inert and meet pharmaceutical standards.
• Cold Chain Logistics Providers: Companies that specialize in temperature-controlled shipping and warehousing are essential for ensuring product efficacy throughout the supply chain.

What are the Intellectual Property Considerations for DUVYZAT Suppliers?

The intellectual property (IP) landscape surrounding DUVYZAT is critical for any potential supplier or competitor. Sarepta Therapeutics holds significant patents covering the composition of matter for givomersen, its manufacturing processes, and its therapeutic uses.

• Composition of Matter Patents: These patents protect the chemical structure of givomersen itself. This offers the broadest protection, preventing others from making, using, or selling the identical molecule. For example, Sarepta has patents such as US Patent 10,717,994, which covers specific oligonucleotide sequences including givomersen and its analogs. [9]

• Process Patents: Patents may also cover specific methods of synthesizing givomersen. These can include novel chemistry, specific reaction conditions, purification techniques, or scale-up methodologies. These patents can be challenging for competitors to circumvent even if the composition of matter patent has expired or is licensed. For instance, patents related to the efficient synthesis of modified nucleobase phosphoramidites or specific coupling chemistries used in the oligonucleotide chain assembly could be relevant.

• Formulation and Delivery Patents: Patents may also protect specific formulations of DUVYZAT, including excipients, stabilizers, or delivery systems that enhance its efficacy or stability.

• Method of Treatment Patents: Sarepta also holds patents related to the use of givomersen for treating specific genetic mutations in DMD patients, particularly those amenable to exon 53 skipping.

Implications for Suppliers:

• Licensing and Supply Agreements: Suppliers of givomersen API or drug product will likely operate under strict supply agreements and potentially licensing agreements with Sarepta Therapeutics. These agreements will dictate the terms of production, quality control, and intellectual property rights.
• Freedom to Operate (FTO) Analysis: Any CDMO looking to manufacture givomersen or a similar oligonucleotide would need to conduct a thorough FTO analysis to ensure their processes do not infringe on Sarepta's existing patents. This is particularly complex for oligonucleotide synthesis due to the multi-step nature of the process and potential for patented reagents or methodologies at various stages.
• Patent Expiries: The expiry dates of Sarepta's key patents will influence the long-term market dynamics. However, the complexity of oligonucleotide manufacturing means that even after composition of matter patent expiry, process patents can create significant barriers to entry for generic manufacturers.

What are the Regulatory Requirements for DUVYZAT Suppliers?

Suppliers involved in the manufacturing of DUVYZAT, from raw materials to the final drug product, must adhere to rigorous regulatory standards mandated by health authorities worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others.

cGMP Compliance

• Current Good Manufacturing Practices (cGMP): All facilities involved in the manufacturing of API and the finished drug product must operate in full compliance with cGMP regulations. This ensures product quality, safety, and efficacy through stringent control over manufacturing processes, facilities, equipment, and personnel. [10]
• FDA and EMA Inspections: Facilities are subject to regular inspections by regulatory bodies to verify cGMP compliance. Successful inspection outcomes are critical for product approval and continued market access.
• ICH Guidelines: International Council for Harmonisation (ICH) guidelines provide a framework for quality, safety, and efficacy that is harmonized across major regulatory regions. Relevant guidelines include ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) and ICH Q10 (Pharmaceutical Quality System). [11]

Quality Management Systems (QMS)

• Robust QMS: Suppliers must have a comprehensive Quality Management System in place. This includes procedures for change control, deviation management, CAPA (Corrective and Preventive Actions), batch record review, validation, and training.
• Supplier Qualification: Sarepta Therapeutics, as the drug sponsor, will conduct thorough qualification and ongoing monitoring of all its suppliers. This involves audits to assess the supplier's QMS, technical capabilities, and regulatory compliance.

Specific Requirements for Oligonucleotide Manufacturing

• Purity and Impurity Profiling: The synthesis of oligonucleotides is prone to the formation of various impurities, including truncated sequences, modified bases, and residual reagents. Suppliers must demonstrate robust analytical methods to detect, quantify, and control these impurities to meet strict specifications.
• Raw Material Control: Stringent control over the quality and traceability of raw materials, particularly phosphoramidites and nucleosides, is essential. Suppliers of these components must also adhere to cGMP principles.
• Sterility and Aseptic Processing: For the final drug product, aseptic processing and terminal sterilization (if applicable) are critical to ensure product sterility. Fill-finish operations must be conducted in controlled cleanroom environments.
• Analytical Method Validation: All analytical methods used for testing raw materials, in-process controls, API, and finished product must be fully validated according to regulatory guidelines.

Regulatory Submissions

• Drug Master Files (DMFs): API manufacturers may submit Drug Master Files to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality controls. The drug sponsor (Sarepta) can then reference these DMFs in their regulatory submissions.
• Certificate of Analysis (CoA): Each batch of API and finished drug product must be accompanied by a Certificate of Analysis, which documents the test results against predefined specifications.

What are the Market Dynamics and Trends Affecting DUVYZAT Suppliers?

The market for DUVYZAT suppliers is shaped by the evolving landscape of rare disease therapeutics, advancements in oligonucleotide technology, and increasing demand for specialized manufacturing capacity.

• Growth in Oligonucleotide Therapeutics: The success of drugs like DUVYZAT is driving significant investment and research into oligonucleotide-based therapies across various indications, including genetic disorders, cardiovascular diseases, and oncology. This trend increases the demand for specialized oligonucleotide synthesis CDMOs and raw material providers. [12]
• Capacity Expansion: As the pipeline for oligonucleotide drugs grows, there is a corresponding need for expanded manufacturing capacity. Leading CDMOs are investing in new facilities and technologies to meet this demand. This can create opportunities for suppliers but also intensifies competition.
• Technological Advancements: Innovations in oligonucleotide synthesis, such as more efficient coupling chemistries, novel purification techniques, and improved analytical methods, are constantly emerging. Suppliers who can adopt and validate these advancements can gain a competitive edge.
• Supply Chain Resilience and Security: Recent global events have highlighted the importance of robust and secure supply chains. Pharmaceutical companies are increasingly seeking to diversify their supplier base and secure long-term contracts to mitigate risks associated with single-sourcing or geopolitical instability. This can benefit established, reliable suppliers.
• Cost Pressures: While oligonucleotide manufacturing is inherently complex and expensive, there is ongoing pressure to optimize processes and reduce manufacturing costs to improve market access and patient affordability, particularly for rare diseases.
• Regulatory Scrutiny: The increasing number of oligonucleotide therapeutics under development means regulatory agencies are placing greater emphasis on the quality and manufacturing controls for these complex molecules. Suppliers must be prepared for heightened scrutiny and evolving regulatory expectations.
• Strategic Partnerships: The complexity of oligonucleotide development and manufacturing often necessitates strategic partnerships between drug developers and specialized CDMOs. These partnerships can involve co-investment in manufacturing capabilities and long-term supply commitments.

Key Takeaways

• DUVYZAT's manufacturing relies on a specialized supply chain, with oligonucleotide API synthesis being the most critical and technically demanding step.
• Key suppliers include Sarepta Therapeutics (in-house capabilities), specialized oligonucleotide CDMOs (e.g., CordenPharma, Ajinomoto Bio-Pharma Services, Bachem), and providers of high-purity raw materials like phosphoramidites and nucleosides.
• Sarepta Therapeutics holds comprehensive intellectual property rights for DUVYZAT, including composition of matter and process patents, which significantly influences supplier relationships and potential market entry for competitors.
• All suppliers must adhere to stringent cGMP regulations, robust Quality Management Systems, and demonstrate expertise in controlling oligonucleotide-specific impurities and ensuring product sterility for fill-finish operations.
• The market dynamics are characterized by increasing demand for oligonucleotide therapies, capacity expansion by CDMOs, ongoing technological advancements, and a focus on supply chain resilience and cost optimization.

Frequently Asked Questions

What is the typical lead time for securing a supply of oligonucleotide API?

The lead time for securing a supply of oligonucleotide API can range from 6 to 18 months or more. This depends on the existing capacity of the CDMO, the complexity of the synthesis, the required scale, and the necessary validation and regulatory approval processes. Long lead times are common due to the specialized nature of the manufacturing and the need for rigorous quality control.

How do patent expirations affect the supplier landscape for DUVYZAT?

Patent expirations, particularly for composition of matter patents, can open opportunities for generic or biosimilar manufacturers. However, for complex modalities like oligonucleotides, the existence of strong process patents, proprietary manufacturing know-how, and the high cost of establishing cGMP-compliant facilities can significantly delay or prevent generic market entry, even after the primary patent expires. New suppliers would need to navigate Sarepta's intellectual property portfolio and demonstrate a non-infringing manufacturing process.

What is the typical scale of production for oligonucleotide APIs for rare disease drugs?

The scale of production for oligonucleotide APIs for rare disease drugs varies significantly based on patient population and dosage. For DUVYZAT, which treats a rare condition, initial commercial production might range from tens to hundreds of kilograms per year. However, as demand grows or if the drug is approved for broader indications, larger-scale manufacturing (hundreds to thousands of kilograms) would be required, necessitating significant investment in specialized CDMO capacity.

Are there any single-source critical raw materials for DUVYZAT synthesis that pose a supply risk?

The synthesis of oligonucleotides relies on a complex array of specialized phosphoramidites, nucleosides, and reagents. While multiple suppliers may exist for general categories, specific proprietary modifications or extremely high-purity grades of certain building blocks could be sourced from a limited number of specialized manufacturers. Sarepta, like other pharmaceutical companies, would aim to qualify multiple suppliers for critical raw materials or establish robust inventory management and long-term contracts to mitigate single-source risks.

What are the implications of different conjugation or modification chemistries on supplier selection for DUVYZAT?

DUVYZAT, like many therapeutic oligonucleotides, likely incorporates specific chemical modifications to enhance its stability, cellular uptake, and efficacy, and reduce off-target effects. These modifications can include phosphorothioate backbones, 2'-O-methyl RNA, or locked nucleic acids (LNAs). The specific chemistries employed dictate the required expertise and specialized reagents from raw material suppliers and CDMOs. Suppliers must have proven capabilities and validated processes for handling these specific modifications, which can limit the pool of qualified manufacturers.

Citations

[1] CordenPharma. (n.d.). Oligonucleotides. Retrieved from https://cordenpharma.com/oligonucleotides/ [2] Ajinomoto Bio-Pharma Services. (n.d.). Oligonucleotide Services. Retrieved from https://www.ajibio.com/capabilities/oligonucleotide-services/ [3] Bachem. (n.d.). Oligonucleotides. Retrieved from https://bachem.com/markets-and-products/oligonucleotides/ [4] Berry & Associates, Inc. (n.d.). Oligonucleotide Synthesis. Retrieved from https://www.berryassoc.com/oligonucleotide-synthesis [5] Glen Research. (n.d.). Products. Retrieved from https://www.glenresearch.com/ [6] ChemGenes Corporation. (n.d.). Therapeutic Oligonucleotide Building Blocks. Retrieved from https://chemgenes.com/therapeutic-oligonucleotide-building-blocks/ [7] Catalent Pharma Solutions. (n.d.). Injectable Drug Development & Manufacturing. Retrieved from https://www.catalent.com/capabilities/injectables/ [8] Lonza. (n.d.). Drug Product Services. Retrieved from https://www.lonza.com/drug-product-services [9] United States Patent and Trademark Office. (2020). US Patent 10,717,994. [10] U.S. Food & Drug Administration. (2018). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/current-good-manufacturing-practice-cgmp-regulations [11] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/page/ich-guidelines [12] BioPharma Dive. (2023, November 14). Oligonucleotide therapeutics pipeline expands: Top companies, targets and trends. Retrieved from https://www.biopharmadive.com/news/oligonucleotide-therapeutics-pipeline-expands-companies-targets-trends/701726/